DISCLAIMER

DISCLAIMER: The author is not a registered stockbroker nor a registered advisor and does not give investment advice. His comments are an expression of opinion only and should not be construed in any manner whatsoever as recommendations to buy or sell a stock, option, future, bond, commodity, index or any other financial instrument at any time. While he believes his statements to be true, they always depend on the reliability of his own credible sources. The author recommends that you consult with a qualified investment advisor, one licensed by appropriate regulatory agencies in your legal jurisdiction, before making any investment decisions, and that you confirm the facts on your own before making important investment commitments.

Thursday, May 6, 2010

GlaxoSmithKline receives UK approval for Combodart

GlaxoSmithKline has been granted a licence approval for Combodart, a new treatment for moderate-to-severe benign prostatic hyperplasia (BPH).

The therapy, which is a combination of dutasteride and tamsulosin hydrochloride, has been approved on the basis of results from a four-year clinical study, which showed its efficacy in reducing the risk of urinary retention and BPH-related surgery.

It is the first treatment to be approved in the UK which combines the positive effects of two separate recommended monotherapies.

Dr Jon Rees, a GP from Bristol with a special interest in urology, said the effectiveness of the treatment makes it more likely that patients will stick to medication regimes and avoid disease progression.

He added: "By delivering all the advantages of two treatments in one single capsule, the arrival of Combodart represents a new approach to BPH management in the UK."

Last week, GlaxoSmithKline published its financial report for the first quarter of 2010, reporting a year-on-year turnover increase of 13 per cent.

Posted by at
Labels: , , , , , , , , , , , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)